Meningococcal vaccine group C conjugate - Nuron Biotech

Drug Profile

Meningococcal vaccine group C conjugate - Nuron Biotech

Alternative Names: Meningitec

Latest Information Update: 24 Dec 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Meningococcal group C infections

Most Recent Events

  • 10 Dec 2012 Nuron Biotech acquires meningococcal vaccine group C conjugate from Pfizer
  • 07 Oct 2002 Launched for prevention of Meningococcal group C infections in Argentina (IM)
  • 07 Oct 2002 Launched for prevention of Meningococcal group C infections in Australia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top